This week in the Orphanet Journal of Rare Diseases, an interesting clinical trial was published. Interesting for three reasons. First, it confirmed an earlier study showing a very common drug (Celebrex) may help patients with a rare disease. Second, it may provide further insight into the pathophysiology of colon cancer developing in patients with familial adenomatous polyposis (FAP). And third, it was a clinical trial in which the intended treatment combination failed to improve outcomes.